NIH | National Cancer Institute | NCI Wiki  

Versions Compared

Old Version 1

changes.mady.by.user Gaheen, Sharon (NIH/NCI) [C]

Saved on

compared with

New Version 2

changes.mady.by.user Gaheen, Sharon (NIH/NCI) [C]

Saved on

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

Page info
title
title

  • Initial release to extend Modified the existing ISA-TAB Specification to support nanomaterial composition and characterization. Extensions -Nano 1.0 version to address user comments. Modifications include:
    • Addition of the Material File to describe the composition and inherent properties of nanomaterials and other small moleculesAddition of a MATERIAL section in the ISA-TAB Investigation File to reference the Material File Name and Material Source NameAddition of fields in the  . Removal of Material File in the Study File.
    • Removal of a separate field in the ISA-TAB Investigation File to support biomedical investigations such as Investigation Disease, Investigation Disease Term Accession Number, Investigation Disease Term Source REF, and Investigation Outcome
    • Addition of fields in the  ISA-TAB  Investigation File to support biomedical studies such as Study Disease, Study Disease Term Accession Number, Study Disease Term Source REF, and Study Outcome
    • Addition of fields in the  ISA-TAB  Investigation File to support the capture of Study Assay Measurement, Study Assay Measurement Term Accession Number, and Study Assay Measurement Term Source REF
    • Addition of field in the ISA-TAB Assay File to support Measurement Values
  • Initial Release. N/A.

Known Issues and Workarounds

    • Assay File to capture Statistics. Users should reference the Statistic in the Measurement Value parameter name in brackets (e.g. Measurement Value [Mean (diameter)]”).
  • Enforced the following business rule:
    1. If the assay is a physico-chemical characterization, there should be no study factors of Study Factor Type nanoparticle sample 
    2. If the assay is a biological assay (in vitro, in vivo), the Study Factor Name and type must be of nanoparticle sample if the assay is applying a nanoparticle sample to a biological system.
  • Fixed ISA-TAB-Nano Investigation File examples to use a pre-fix for Term Accessoin Number and Term Source REF in the Investigation File per the ISA-TAB specificatoin (not required for other ISA-TAB files)
  • Fixed ISA-TAB-Nano Study File examples to follow the appropriate ISA-TAB ordering requirements
    • In the Study File, order Protocol REF and associated parameters immediately after Source Name and associated attributes and before Sample Name and Factor Values
  • Fixed ISA-TAB-Nano Assay File examples to follow the appropriate ISA-TAB ordering requirements
    • In the Assay File, order Protocol REF to be included after Sample Name
  • Fixed ISA-TAB-Nano Assay File examples to remove the Source Name.  Only the Sample Name should be referenced in the Assay File.

Known Issues and Workarounds

  • Currently, ISA-TAB does not support Study Grant Number and Study Funding Agency as standard fields in the Investigation Files. These fields can be added in a comments field.
  • Grouping of assays is subjective to the particular study. Recommend grouping of assays that use the same sample under one study.
  • For studies involving insertion of tumor cells into mice and the application of a nanoparticle as a treatment, the tumor cells should be parameter values and the nanoparticle should be factor values
    Initial Release. N/A
    .